Additionally, the 36-month beta value for CTSO is 0.59. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CTSO is 46.55M and currently, short sellers hold a 2.90% ratio of that float. The average trading volume of CTSO on November 05, 2024 was 92.22K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CTSO) stock’s latest price update
The stock price of Cytosorbents Corp (NASDAQ: CTSO) has plunged by -12.95 when compared to previous closing price of 1.00, but the company has seen a -13.81% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-01 that CytoSorbents files for FDA De Novo marketing approval of DrugSorb-ATR to reduce the severity of CABG-related bleeding due to the blood thinner ticagrelor
CTSO’s Market Performance
Cytosorbents Corp (CTSO) has seen a -13.81% fall in stock performance for the week, with a -26.85% decline in the past month and a -13.81% plunge in the past quarter. The volatility ratio for the week is 6.38%, and the volatility levels for the past 30 days are at 6.42% for CTSO. The simple moving average for the past 20 days is -17.53% for CTSO’s stock, with a -12.42% simple moving average for the past 200 days.
Analysts’ Opinion of CTSO
Many brokerage firms have already submitted their reports for CTSO stocks, with B. Riley Securities repeating the rating for CTSO by listing it as a “Buy.” The predicted price for CTSO in the upcoming period, according to B. Riley Securities is $4 based on the research report published on September 07, 2023 of the previous year 2023.
B. Riley Securities, on the other hand, stated in their research note that they expect to see CTSO reach a price target of $10. The rating they have provided for CTSO stocks is “Buy” according to the report published on October 14th, 2021.
Jefferies gave a rating of “Buy” to CTSO, setting the target price at $15 in the report published on September 17th of the previous year.
CTSO Trading at -24.11% from the 50-Day Moving Average
After a stumble in the market that brought CTSO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.51% of loss for the given period.
Volatility was left at 6.42%, however, over the last 30 days, the volatility rate increased by 6.38%, as shares sank -22.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.40% lower at present.
During the last 5 trading sessions, CTSO fell by -13.81%, which changed the moving average for the period of 200-days by -9.32% in comparison to the 20-day moving average, which settled at $1.0555. In addition, Cytosorbents Corp saw -21.58% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CTSO starting from Sobel Alan D., who purchase 22,557 shares at the price of $1.33 back on Dec 13 ’23. After this action, Sobel Alan D. now owns 101,857 shares of Cytosorbents Corp, valued at $30,001 using the latest closing price.
Deliargyris Efthymios, the Chief Medical Officer of Cytosorbents Corp, purchase 22,557 shares at $1.33 during a trade that took place back on Dec 13 ’23, which means that Deliargyris Efthymios is holding 348,433 shares at $30,001 based on the most recent closing price.
Stock Fundamentals for CTSO
Current profitability levels for the company are sitting at:
- -0.68 for the present operating margin
- 0.64 for the gross margin
The net margin for Cytosorbents Corp stands at -0.71. The total capital return value is set at -0.57. Equity return is now at value -125.05, with -48.23 for asset returns.
Based on Cytosorbents Corp (CTSO), the company’s capital structure generated 0.46 points at debt to capital in total, while cash flow to debt ratio is standing at -1.51. The debt to equity ratio resting at 0.84. The interest coverage ratio of the stock is 244.79.
Currently, EBITDA for the company is -28.53 million with net debt to EBITDA at -0.8. When we switch over and look at the enterprise to sales, we see a ratio of 1.82. The receivables turnover for the company is 4.62for trailing twelve months and the total asset turnover is 0.68. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.12.
Conclusion
In conclusion, Cytosorbents Corp (CTSO) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
